On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN (filgrastim). FILKRI was developed by Accord BioPharma, the U.S.

Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA. Zarxio (filgrastim-sndz) is a biosimilar ...

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...

TWO young women from Jersey – one who gave a life-saving donation and another whose life was saved by a stranger – have joined forces to urge Islanders to take a simple step that could mean the ...

Polypeptides that are being discovered by the biotechnology industry hold great promise as new drug candidates to target specific disease symptoms. However, polypeptide drugs are rapidly degraded by ...

Clinical data from randomized studies demonstrated that Filkri is highly similar to the reference product with no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity. The ...

Camber is expanding its launching four new generics. The company is releasing plerixafor injection, which is a generic for Mozobil. It is available in 24 mg/1.2 ml (20 mg/ml). Ple ...